• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

开发一种优化的方案,用于在单细胞水平上对胸腔积液中的肿瘤细胞进行分子谱分析。

Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level.

机构信息

Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.

Department of Respiratory Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan.

出版信息

Cancer Sci. 2021 May;112(5):2006-2019. doi: 10.1111/cas.14821. Epub 2021 Apr 2.

DOI:10.1111/cas.14821
PMID:33484069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8088920/
Abstract

Liquid biopsy analyzes the current status of primary tumors and their metastatic regions. We aimed to develop an optimized protocol for single-cell sequencing of floating tumor cells (FTCs) in pleural effusion as a laboratory test. FTCs were enriched using a negative selection of white blood cells by a magnetic-activated cell sorting system, and CD45-negative and cytokeratin-positive selection using a microfluidic cell separation system with a dielectrophoretic array. The enriched tumor cells were subjected to whole-genome amplification (WGA) followed by genome sequencing. The FTC analysis detected an EGFR exon 19 deletion in Case 1 (12/19 cells, 63.2%), and EML4-ALK fusion (17/20 cells, 85%) with an alectinib-resistant mutation of ALK (p.G1202R) in Case 2. To eliminate WGA-associated errors and increase the uniformity of the WGA product, the protocol was revised to sequence multiple single FTCs individually. An analytical pipeline, accurate single-cell mutation detector (ASMD), was developed to identify somatic mutations of FTCs. The large numbers of WGA-associated errors were cleaned up, and the somatic mutations detected in FTCs by ASMD were concordant with those found in tissue specimens. This protocol is applicable to circulating tumor cells analysis of peripheral blood and expands the possibility of utilizing molecular profiling of cancers.

摘要

液体活检分析原发性肿瘤及其转移部位的当前状态。我们旨在开发一种优化的方案,用于对胸腔积液中的游离肿瘤细胞(FTCs)进行单细胞测序,作为实验室检测。通过磁激活细胞分选系统对白细胞进行阴性选择,使用带有介电泳阵列的微流控细胞分离系统对 CD45 阴性和细胞角蛋白阳性进行选择,从而富集 FTCs。对富集的肿瘤细胞进行全基因组扩增(WGA),然后进行基因组测序。FTC 分析在病例 1 中检测到 EGFR 外显子 19 缺失(19 个细胞中的 12 个,63.2%),在病例 2 中检测到 EML4-ALK 融合(20 个细胞中的 17 个,85%),并伴有 ALK(p.G1202R)耐药突变。为了消除 WGA 相关错误并提高 WGA 产物的均匀性,修订了方案,以便单独对多个单个 FTC 进行测序。开发了一种分析管道,即准确的单细胞突变检测器(ASMD),用于鉴定 FTC 的体细胞突变。大量的 WGA 相关错误被清理掉,ASMD 在 FTC 中检测到的体细胞突变与在组织标本中发现的突变一致。该方案适用于外周血循环肿瘤细胞的分析,并扩大了利用癌症分子谱进行分析的可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/8088920/e01fdcdd3d01/CAS-112-2006-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/8088920/ae9b169f31fa/CAS-112-2006-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/8088920/f3e4350b9fa3/CAS-112-2006-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/8088920/54c2d8a1ee59/CAS-112-2006-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/8088920/ff19d4a7585c/CAS-112-2006-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/8088920/e01fdcdd3d01/CAS-112-2006-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/8088920/ae9b169f31fa/CAS-112-2006-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/8088920/f3e4350b9fa3/CAS-112-2006-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/8088920/54c2d8a1ee59/CAS-112-2006-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/8088920/ff19d4a7585c/CAS-112-2006-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/8088920/e01fdcdd3d01/CAS-112-2006-g003.jpg

相似文献

1
Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level.开发一种优化的方案,用于在单细胞水平上对胸腔积液中的肿瘤细胞进行分子谱分析。
Cancer Sci. 2021 May;112(5):2006-2019. doi: 10.1111/cas.14821. Epub 2021 Apr 2.
2
Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in -Rearranged Non-Small-Cell Lung Cancer.通过对 - 重排非小细胞肺癌循环肿瘤细胞测序鉴定出的 ALK 抑制剂获得性耐药突变。
Clin Cancer Res. 2019 Nov 15;25(22):6671-6682. doi: 10.1158/1078-0432.CCR-19-1176. Epub 2019 Aug 22.
3
Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.高肿瘤突变负荷的 ALK 阳性肺癌中阿来替尼耐药的快速获得。
J Thorac Oncol. 2019 Nov;14(11):2009-2018. doi: 10.1016/j.jtho.2019.07.017. Epub 2019 Jul 30.
4
Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.获得性多重突变 ALK I1171N、L1196M 和 G1202R 介导 EML4-ALK 重排恶性胸膜间皮瘤对 lorlatinib 的耐药性:一例报告。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620935770. doi: 10.1177/1753466620935770.
5
Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).针对携带EML4-ALK融合基因的阿来替尼难治性非小细胞肺癌患者的从实验室到临床研究的方案设计(ALRIGHT/OLCSG1405)
Clin Lung Cancer. 2016 Nov;17(6):602-605. doi: 10.1016/j.cllc.2016.05.005. Epub 2016 Jun 2.
6
A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.携带有 EML4-ALK 融合基因的新型人肺腺癌细胞系。
Jpn J Clin Oncol. 2014 Oct;44(10):963-8. doi: 10.1093/jjco/hyu110. Epub 2014 Aug 28.
7
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.EML4-ALK 易位预示 EGFR 野生型肺腺癌患者的预后更好。
J Thorac Oncol. 2012 Jan;7(1):98-104. doi: 10.1097/JTO.0b013e3182370e30.
8
Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?ALK G1202R溶剂前沿突变与小细胞肺癌转化双重出现作为对第二代ALK抑制剂的耐药机制,且未预先接触过克唑替尼。仅依靠液体再活检的陷阱?
Lung Cancer. 2017 Apr;106:110-114. doi: 10.1016/j.lungcan.2017.02.005. Epub 2017 Feb 9.
9
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.下一代测序揭示了一种新型 NSCLC ALK F1174V 突变,并证实 ALK G1202R 突变使对克唑替尼治疗后进展的 ALK 重排 NSCLC 患者对艾乐替尼(CH5424802/RO5424802)具有高水平耐药性。
J Thorac Oncol. 2014 Apr;9(4):549-53. doi: 10.1097/JTO.0000000000000094.
10
Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI-Treated Non-Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy.病例报告:基于二代测序的液体活检揭示序贯使用ALK酪氨酸激酶抑制剂治疗的非小细胞肺癌中ALK激活突变的时间异质性
Clin Lung Cancer. 2019 May;20(3):e229-e232. doi: 10.1016/j.cllc.2019.02.014. Epub 2019 Feb 27.

引用本文的文献

1
Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing.评估并改进用于快速药敏试验的恶性积液中肿瘤细胞分离技术。
Mol Oncol. 2025 Sep;19(9):2474-2490. doi: 10.1002/1878-0261.70072. Epub 2025 Jun 17.
2
Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry.利用液质联用技术在个体化水平上对肺癌患者液体活检中的 EMT 和 MET 细胞状态进行表型分析。
Sci Rep. 2023 Dec 8;13(1):21781. doi: 10.1038/s41598-023-46458-5.
3
Single-Circulating Tumor Cell Whole Genome Amplification to Unravel Cancer Heterogeneity and Actionable Biomarkers.

本文引用的文献

1
Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.晚期间变性淋巴瘤激酶阳性非小细胞肺癌中洛拉替尼的耐药突变与疗效。
J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20.
2
Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens.通过从福尔马林固定石蜡包埋标本中进行靶向富集,对癌症进行全面的分子谱分析。
Cancer Sci. 2019 Apr;110(4):1464-1479. doi: 10.1111/cas.13968. Epub 2019 Mar 5.
3
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
单循环肿瘤细胞全基因组扩增以揭示癌症异质性和可行的生物标志物。
Int J Mol Sci. 2022 Jul 29;23(15):8386. doi: 10.3390/ijms23158386.
4
Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram.基于列线图的恶性胸腔积液早期诊断评分系统的开发与验证
Front Oncol. 2021 Dec 7;11:775079. doi: 10.3389/fonc.2021.775079. eCollection 2021.
在组织基因分型样本不足的晚期肺腺癌患者中,基于血浆的数字下一代测序的临床实用性。
Ann Oncol. 2019 Feb 1;30(2):290-296. doi: 10.1093/annonc/mdy512.
4
Next-Generation Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues.超越组织的下一代新型非侵入性癌症分子诊断平台。
Am Soc Clin Oncol Educ Book. 2018 May 23;38(38):964-977. doi: 10.1200/EDBK_199767.
5
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.液体活检在晚期非小细胞肺癌(NSCLC)中的应用:国际肺癌研究协会(IASLC)立场文件。
J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6.
6
Clinical Utility of Cell-Free DNA for the Detection of Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.游离 DNA 在非小细胞肺癌中检测 ALK 抑制剂耐药的融合和基因组机制的临床效用。
Clin Cancer Res. 2018 Jun 15;24(12):2758-2770. doi: 10.1158/1078-0432.CCR-17-2588. Epub 2018 Mar 29.
7
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.癌症患者循环肿瘤 DNA 分析:美国临床肿瘤学会和美国病理学家学会联合审查。
J Clin Oncol. 2018 Jun 1;36(16):1631-1641. doi: 10.1200/JCO.2017.76.8671. Epub 2018 Mar 5.
8
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.EML4-ALK 变异对 ALK 阳性肺癌耐药机制和临床结局的影响。
J Clin Oncol. 2018 Apr 20;36(12):1199-1206. doi: 10.1200/JCO.2017.76.2294. Epub 2018 Jan 26.
9
Detection and localization of surgically resectable cancers with a multi-analyte blood test.通过多分析物血液检测对外科可切除癌症进行检测和定位。
Science. 2018 Feb 23;359(6378):926-930. doi: 10.1126/science.aar3247. Epub 2018 Jan 18.
10
Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells.单个癌细胞的全基因组扩增与下一代测序性能的比较研究。
Oncotarget. 2016 Jul 19;8(34):56066-56080. doi: 10.18632/oncotarget.10701. eCollection 2017 Aug 22.